Proportion of participants with recurrence of uveitis · people with chronic non‐infectious uveitis
Steroid implant may leads to lower proportion of participants with recurrence of uveitis compared with sham procedure (low certainty).
1 finding from 1 review
Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · people with chronic non‐infectious uveitis
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Proportion of eyes with cataract formation or progression, or surgery · people with chronic non‐infectious uveitis
Steroid implant may leads to higher proportion of eyes with cataract formation or progression, or surgery compared with standard‐of‐care therapy (low certainty).
1 finding from 1 review
RR 2.71 [2.06, 3.56]
Studies not reported
Low
Proportion of eyes with elevated IOP or receiving intervention · people with chronic non‐infectious uveitis
Steroid implant probably leads to higher proportion of eyes with elevated IOP or receiving intervention compared with standard‐of‐care therapy (moderate certainty).
1 finding from 1 review
RR 3.64 [2.71, 4.87]
Studies not reported
Moderate
Proportion of eyes with endophthalmitis**** · people with chronic non‐infectious uveitis
Steroid implant showed no clear difference in proportion of eyes with endophthalmitis**** compared with standard‐of‐care therapy (moderate certainty).
1 finding from 1 review
RR 7.3 [0.91, 58.72]
Studies not reported
Moderate
Proportion of eyes with retinal tear or detachment · people with chronic non‐infectious uveitis
Steroid implant showed no clear difference in proportion of eyes with retinal tear or detachment compared with standard‐of‐care therapy (moderate certainty).
1 finding from 1 review
RR 2.07 [0.51, 8.4]
Studies not reported
Moderate
Mean difference in BCVA (logMAR) · people with chronic non‐infectious uveitis
1 finding from 1 review
Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · people with chronic non‐infectious uveitis
1 finding from 1 review
Proportion of eyes with cataract formation or progression, or surgery · people with chronic non‐infectious uveitis
Steroid implant may leads to higher proportion of participants with cataract formation/progression, or… compared with sham procedure (low certainty).
1 finding from 1 review
Proportion of participants with elevated IOP or receiving intervention · people with chronic non‐infectious uveitis
Steroid implant probably leads to higher proportion of participants with elevated IOP or receiving intervention compared with sham procedure (moderate certainty).
1 finding from 1 review
Proportion of participants with endophthalmitis · people with chronic non‐infectious uveitis
Steroid implant showed no clear difference in proportion of participants with endophthalmitis compared with sham procedure (moderate certainty).
1 finding from 1 review
Proportion of participants with retinal tear or detachment · people with chronic non‐infectious uveitis
Steroid implant showed no clear difference in proportion of participants with retinal tear or detachment compared with sham procedure (moderate certainty).
1 finding from 1 review
Proportion of eyes with recurrence of uveitis · people with chronic non‐infectious uveitis
Steroid implant may leads to lower proportion of eyes with recurrence of uveitis compared with standard‐of‐care therapy (low certainty).
1 finding from 1 review
RR 0.46 [0.35, 0.6]
Studies not reported
Low
Mean difference in BCVA (logMAR) · people with chronic non‐infectious uveitis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal dexamethasone implant 0.7 mg changes surgery for glaucoma ‐ 24 months compared with intravitreal antiVEGF (very low certainty).
1 finding from 1 review
RR 3.02 [0.12, 73.56]
Studies not reported
Very low
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Change in retinal thickness (micron) (negative is better) · macular edema in diabetes
1 finding from 1 review